From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...

The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...